Upstream Bio Announces Upsized $293 Million IPO
October 17, 2024
October 17, 2024
PALO ALTO, California, Oct. 17 -- Cooley, a law firm, issued the following news release:
New York - October 15, 2024 - Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering (IPO).
Upstream Bio offered 17,250,000 shares priced at $17 per share, which includes the full exercise of the underwriters' option to purchase 2,250,000 additiona . . .
New York - October 15, 2024 - Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering (IPO).
Upstream Bio offered 17,250,000 shares priced at $17 per share, which includes the full exercise of the underwriters' option to purchase 2,250,000 additiona . . .